Novartis is moving quickly to outline how radiopharmaceutical manufacturing fits into its planned $23 billion investment in the U.S. Soon after unveiling plans for a new cancer drug production facility in Florida, the company has now disclosed intentions to establish an additional site in Texas.
The planned 46,000-square-foot radioligand therapy (RLT) manufacturing plant will be located in Denton, Texas, within the broader Dallas-Fort Worth region. According to a February 25 company announcement, the facility will represent the fifth operational or proposed radiopharmaceutical production site in Novartis’ U.S. network.
Construction is expected to begin this year, with operations targeted to start in 2028. The new site is projected to create employment opportunities across areas such as advanced manufacturing, quality assurance and operations and bioengineering, though the company has not detailed the number of positions to be added.
Currently, Novartis markets two FDA-approved radioligand therapies, namely Lutathera and Pluvicto, which are indicated for neuroendocrine tumors and prostate cancer, respectively. Radiopharmaceuticals work by delivering radioactive compounds directly to cancer cells. While interest in these therapies has surged in oncology research and development, the total number of RLTs cleared for use in the U.S. remains limited.
In its announcement, Novartis did not specifically mention Lutathera or Pluvicto. However, the company said the forthcoming Denton facility will support patients across the southern United States and expand overall network capacity as RLT moves into earlier stages of treatment and targets a broader range of tumor types.
Vas Narasimhan, chief executive officer of the firm, said in a statement that RLT holds transformative potential for cancer care. He added that establishing a fifth U.S.-based RLT manufacturing site would enhance the company’s ability to address rising demand while strengthening the infrastructure needed to deliver these advanced therapies with the required speed and accuracy.
The planned Texas facility will join four other Novartis radiopharmaceutical manufacturing sites located in Florida, New Jersey,California and Indiana.
In early January, the company detailed plans for a separate 35,000-square-foot RLT production plant in Winter Park, Florida, which is expected to begin operations by 2029.
Both new facilities are part of the wider $23 billion U.S. investment initiative the firm announced last April, aligning with a wave of large-scale domestic manufacturing commitments from pharmaceutical companies seeking to mitigate potential tariff risks under the administration of President Donald Trump.
At that time, Novartis pledged to construct or expand 10 U.S. facilities over a period of five years, including four new manufacturing plants and the two radioligand therapy sites now planned for Florida and Texas. The company said its non-RLT investments would focus on producing biologic drug substances, finished drug products, chemical compounds and oral solid medications.
Separately, Novartis has continued to secure supplies of radioactive isotopes critical to RLT production. Earlier this month, the company entered into an agreement with Niowave to obtain scalable quantities of Actinium-225 to support the development and manufacturing of its radioligand therapy portfolio.
Novartis’ Strategic Expansion in the U.S.
The selection of Texas reflects Novartis’ commitment to expanding manufacturing capacity nationwide under a multibillion-dollar investment plan.
What the Texas Facility Will Produce
Novartis plans to focus on radioligand therapies — precision cancer treatments that combine targeted radiation with molecular medicine.
Economic and Job Impact
The Novartis Denton site is expected to generate skilled jobs in bioengineering and manufacturing, supporting regional economic development.
The planned Novartis facility will produce radioligand therapy (RLT) cancer drugs — specialized treatments that deliver targeted radiation to tumors — and is part of the company’s broader $23 billion investment strategy to expand its U.S. manufacturing footprint.
The new Novartis production site will span about 46,000 square feet and is expected to begin construction this year, with operations slated to start in 2028. By locating the facility in Texas, Novartis aims to strengthen its ability to deliver next-generation cancer treatments faster and closer to patients in the southern U.S. region.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
